ATE182076T1 - Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden - Google Patents

Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden

Info

Publication number: ATE182076T1
Authority: AT; Austria
Prior art keywords: nmda receptor; neuronal damage; mediated neuronal; mammal; receptor complex
Prior art date: 1991-04-19

Application number

AT92910911T

Other languages

English (en)

Inventor

Stuart A Lipton

Original Assignee

Childrens Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-19

Filing date

1992-04-17

Publication date

1999-07-15

1992-04-17 Application filed by Childrens Medical Center filed Critical Childrens Medical Center

1999-07-15 Application granted granted Critical

1999-07-15 Publication of ATE182076T1 publication Critical patent/ATE182076T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)

AT92910911T 1991-04-19 1992-04-17 Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden ATE182076T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US68896591A	1991-04-19	1991-04-19

Publications (1)

Publication Number	Publication Date
ATE182076T1 true ATE182076T1 (de)	1999-07-15

Family

ID=24766524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92910911T ATE182076T1 (de)	1991-04-19	1992-04-17	Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden

Country Status (7)

Country	Link
US (1)	US5234956A (de)
EP (1)	EP0581856B1 (de)
JP (2)	JPH06506690A (de)
AT (1)	ATE182076T1 (de)
DE (1)	DE69229598T2 (de)
ES (1)	ES2134804T3 (de)
WO (1)	WO1992018112A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721365A (en) *	1989-09-15	1998-02-24	Us Health	N-substituted piperazine NONOates
US5208233A (en) *	1989-09-15	1993-05-04	The United States Of America As Represented By The Department Of Health And Human Services	Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5455279A (en) *	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) *	1991-04-19	2000-06-06	Children's Medical Center Corporation	Method of preventing NMDA receptor complex-mediated neuronal damage
US5691423A (en) *	1992-08-24	1997-11-25	The United States Of America As Represented By The Department Of Health And Human Services	Polysaccharide-bound nitric oxide-nucleophile adducts
US5910316A (en)	1992-08-24	1999-06-08	The United States Of America, As Represented By The Department Of Health And Human Services	Use of nitric oxide-releasing agents to treat impotency
US5385940A (en) *	1992-11-05	1995-01-31	The General Hospital Corporation	Treatment of stroke with nitric-oxide releasing compounds
PT669929E (pt) *	1992-11-13	2007-04-30	Immunex Corp	Ligando de elk, uma citoquina
DE4305881C1 (de) *	1993-02-26	1994-03-03	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
US5475007A (en) *	1993-05-28	1995-12-12	The Regents Of The University Of California	1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
US5840759A (en) *	1993-10-08	1998-11-24	The United States Of America As Represented By The Department Of Health And Human Services	Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
EP0722320B1 (de) *	1993-10-08	2000-07-19	THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services	Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
US6303769B1 (en)	1994-07-08	2001-10-16	Immunex Corporation	Lerk-5 dna
CA2132690A1 (en) *	1994-09-22	1996-03-23	Dean Willis	Control and modulation of inflammatory response in humans in need of such control and modulation
US6066333A (en) *	1994-09-22	2000-05-23	William Harvey Research Limited	Pharmaceutical control of inflammation
US5648101A (en) *	1994-11-14	1997-07-15	Tawashi; Rashad	Drug delivery of nitric oxide
US5714511A (en) *	1995-07-31	1998-02-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US6310052B1 (en)	1996-06-04	2001-10-30	Queen's University At Kingston	Nitrate esters and their use for neurological conditions
US20050137191A1 (en) *	1996-06-04	2005-06-23	Thatcher Gregory R.	Nitrate esters and their use for mitigating cellular damage
US6008221A (en) *	1996-11-06	1999-12-28	Bristol-Myers Squibb Company	Method for treating Alzheimer's disease with folic acid
JPH11217330A (ja) *	1998-01-30	1999-08-10	Sumitomo Pharmaceut Co Ltd	神経栄養因子分泌促進剤
US6261594B1 (en)	1998-11-25	2001-07-17	The University Of Akron	Chitosan-based nitric oxide donor compositions
US6444702B1 (en)	2000-02-22	2002-09-03	Neuromolecular, Inc.	Aminoadamantane derivatives as therapeutic agents
GB0007193D0 (en) *	2000-03-25	2000-05-17	Univ Manchester	Treatment of movrmrnt disorders
US20040110691A1 (en) *	2001-11-13	2004-06-10	Stamler Jonathan S.	Thiol reactive agents as a therapeutic modality
AR046314A1 (es)	2003-11-05	2005-11-30	Merz Pharma Gmbh & Co Kgaa	Composiciones que comprenden ciclohexilaminas y aminoadamantanos
ES2483126T3 (es)	2004-06-17	2014-08-05	Merz Pharma Gmbh & Co. Kgaa	Formulaciones de formas de dosificación de neramexano
EP2111858A1 (de)	2008-04-25	2009-10-28	EPFL Ecole Polytechnique Fédérale de Lausanne	Neue Behandlung für Morbus Alzheimer
WO2009152483A2 (en) *	2008-06-12	2009-12-17	University Of Alabama Huntsville	Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma
WO2010005687A1 (en) *	2008-06-12	2010-01-14	University Of Alabama Huntsville	Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases or trauma
NZ601635A (en)	2010-01-27	2013-06-28	Takeda Pharmaceutical	Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PT2854841T (pt)	2012-06-04	2017-05-15	Diamedica Inc	Isoformas de glicosilação da calicreína 1 em tecido humano
US11857608B2 (en)	2017-03-09	2024-01-02	Diamedica Inc.	Dosage forms of tissue kallikrein 1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4806543A (en) *	1986-11-25	1989-02-21	Board Of Trustees Of The Leland Stanford Junior University	Method and compositions for reducing neurotoxic injury
WO1991002810A1 (en) *	1989-08-09	1991-03-07	The Children's Medical Center Corporation	Nmda oxidizing agents for protecting neurons from injury
US5091391A (en) *	1990-08-16	1992-02-25	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Method of resisting neurodegenerative disorders

1992
- 1992-04-17 WO PCT/US1992/003196 patent/WO1992018112A1/en not_active Ceased
- 1992-04-17 EP EP92910911A patent/EP0581856B1/de not_active Expired - Lifetime
- 1992-04-17 ES ES92910911T patent/ES2134804T3/es not_active Expired - Lifetime
- 1992-04-17 DE DE69229598T patent/DE69229598T2/de not_active Expired - Lifetime
- 1992-04-17 JP JP4510067A patent/JPH06506690A/ja active Pending
- 1992-04-17 AT AT92910911T patent/ATE182076T1/de active
- 1992-09-22 US US07/949,342 patent/US5234956A/en not_active Expired - Lifetime
2005
- 2005-12-16 JP JP2005362538A patent/JP2006117693A/ja active Pending

Also Published As

Publication number	Publication date
EP0581856A1 (de)	1994-02-09
JP2006117693A (ja)	2006-05-11
EP0581856A4 (de)	1994-03-02
WO1992018112A1 (en)	1992-10-29
EP0581856B1 (de)	1999-07-14
DE69229598D1 (de)	1999-08-19
JPH06506690A (ja)	1994-07-28
DE69229598T2 (de)	1999-11-04
US5234956A (en)	1993-08-10
ES2134804T3 (es)	1999-10-16

Publication	Publication Date	Title
DE69229598D1 (de)	1999-08-19	Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
AU5348194A (en)	1994-04-12	Method of preventing nmda receptor complex-mediated neuronal damage
FI932254A7 (fi)	1993-07-02	Menetelmä dipalmitoyylifosfaridyylikoliinidispersioiden antamiseksi
AR038434A2 (es)	2005-01-12	Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
ATE128143T1 (de)	1995-10-15	17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
ES8604548A1 (es)	1986-02-01	Procedimiento para preparar nuevos derivados de acidos feni-laceticos
CA2002859A1 (en)	1990-05-29	Method of treating epithelial disorders
ATE201597T1 (de)	2001-06-15	Verabreichung von riluzol zur behandlung von neuro-aids
ATE107515T1 (de)	1994-07-15	Zusammensetzung zur behandlung von entzündung.
FI953899A0 (fi)	1995-08-18	Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
FI943817A7 (fi)	1994-08-19	Bisyklo/2.2.2/oktaanijohdannaisia kolestokystokiniinin inhibiittoreina
SE8202380L (sv)	1982-10-17	Analgetisk komposition
ES2092646T3 (es)	1996-12-01	Metanoantracenos como antagonistas de dopamina.
NO923200D0 (no)	1992-08-14	Piperidin-derivater
MX9604765A (es)	1998-05-31	Derivados de 5-heterociclico 1,5-benzodiazepinas que modulan la cck o gastrina.
ES2134313T3 (es)	1999-10-01	Utilizacion de derivados de pregnano para el tratamiento de tumores.
MX9704034A (es)	1998-02-28	Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2187534T3 (es)	2003-06-16	Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2093357T3 (es)	1996-12-16	Metodo de tratamiento de la alopecia.
ES2084878T3 (es)	1996-05-16	Sal colina de diclofenac, un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FI884960A0 (fi)	1988-10-27	Anvaendning av 2-pyrimidinyl-1-piperazin-derivat.
TR200103561T2 (tr)	2002-04-22	Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
PT95118A (pt)	1991-05-22	Metodo para o tratamento de dependencias quimicas utilizando sertralina
AR011178A1 (es)	2000-08-02	Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto
UA27781C2 (uk)	2000-10-16	Спосіб лікування метастазів пухлин